{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:09:34Z","timestamp":1788869374888,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cllc.2026.07.007","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:32:28Z","timestamp":1784388748000},"page":"113-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy in Patients With Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: A Multi-institutional Case Series"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-3926","authenticated-orcid":false,"given":"K\u00fcbra","family":"Canaslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte","family":"Primdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Iams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidi","family":"Lugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafeez","family":"Chatoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticiana","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3451-0303","authenticated-orcid":false,"given":"Shailee","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2026.07.007_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00194096","article-title":"Immunopathology of the Lambert-Eaton myasthenic syndrome","volume":"17","author":"Lang","year":"1995","journal-title":"Springer Semin Immunopathol"},{"issue":"1\u20132","key":"10.1016\/j.cllc.2026.07.007_bib0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2005.04.001","article-title":"P\/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer","volume":"164","author":"Wirtz","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.cllc.2026.07.007_bib0003","first-page":"31","article-title":"The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma","volume":"2","author":"Briggs","year":"2013","journal-title":"Immunotargets Ther"},{"issue":"1","key":"10.1016\/j.cllc.2026.07.007_bib0004","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JTO.0b013e3181c3f4f1","article-title":"Prospective study into the incidence of Lambert-Eaton myasthenic syndrome in small cell lung cancer","volume":"5","author":"Payne","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"10212","key":"10.1016\/j.cllc.2026.07.007_bib0005","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.cllc.2026.07.007_bib0006","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.cllc.2026.07.007_bib0007","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cllc.2026.07.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.13727","article-title":"Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders","volume":"8","author":"Fletcher","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cllc.2026.07.007_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114148","article-title":"A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease","volume":"207","author":"Lopez-Olivo","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2026.07.007_bib0010","article-title":"The efficacy and safety of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2026.07.007_bib0011","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/ol.2022.13513","article-title":"Combined treatment with radiotherapy, chemotherapy and avelumab results in regression of metastatic Merkel cell carcinoma and improvement of associated Lambert-Eaton myasthenic syndrome: a case report","volume":"24","author":"Green","year":"2022","journal-title":"Oncol Lett"},{"issue":"7","key":"10.1016\/j.cllc.2026.07.007_bib0012","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2169\/internalmedicine.0072-22","article-title":"Lambert-Eaton Myasthenic Syndrome recurrence induced by Pembrolizumab in a patient with non-small-cell lung cancer","volume":"62","author":"Takigawa","year":"2023","journal-title":"Intern Med"},{"key":"10.1016\/j.cllc.2026.07.007_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578485","article-title":"Pre-existing Lambert-Eaton myasthenic syndrome and scleroderma in a patient with neuroendocrine carcinoma undergoing immune checkpoint inhibitor cancer immunotherapy","volume":"398","author":"Vorasoot","year":"2025","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.cllc.2026.07.007_bib0014","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.cllc.2021.09.001","article-title":"An extensive-stage small-cell lung cancer case with preexisting Lambert-Eaton myasthenic syndrome successfully treated with an immune checkpoint inhibitor","volume":"23","author":"Sakaguchi","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2026.07.007_bib0015","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s42466-020-00099-5","article-title":"Immunoglobulins to mitigate paraneoplastic Lambert-Eaton Myasthenic syndrome under checkpoint inhibition in Merkel cell carcinoma","volume":"2","author":"Dohrn","year":"2020","journal-title":"Neurol Res Pract"},{"key":"10.1016\/j.cllc.2026.07.007_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1608934","article-title":"Mechanisms of autoimmune-mediated paraneoplastic syndromes: immune tolerance and disease pathogenesis","volume":"16","author":"P\u00e9rez-Bucio","year":"2025","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.cllc.2026.07.007_bib0017","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41582-024-01001-6","article-title":"Peripheral nervous system immune-related adverse events due to checkpoint inhibition","volume":"20","author":"O'Hare","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.cllc.2026.07.007_bib0018","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00415-021-10870-6","article-title":"How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update","volume":"269","author":"Vogrig","year":"2022","journal-title":"J Neurol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:19:56Z","timestamp":1788866396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525730426001002"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.07.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in Patients With Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: A Multi-institutional Case Series","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}